Immunohistochemical assessment of p170 provides prognostic information in endometrial carcinoma

Histopathology

Volumn 34, Issue 1, 1999, Pages 43-50

  Bonatz, G ^a   Luttes J ^b   Hamann, S ^b   Mettler, L ^b   Jonat, W ^b   Parwaresch, R ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

Endometrial adenocarcinoma; Immunohistochemistry; Ki S4; Ki S5; Monoclonal antibodies; p170; Proliferative activity

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0032966177     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00564.x     Document Type: Article

References (30)

1. 1. Gudmundsson TE, Högberg T. Alm P et al. The prognostic information of DNA ploidy and S-phase fraction may vary with histologic grade in endometrial carcinoma. Acta Oncol. 1995; 34; 803-812.
2. 2. Maneschi M, Maneschi F, Geraci P. Surgical pathological staging of endometrial carcinoma and results of treatment. Eur. J. Gynecol. Oncol. 1992; 13; 30-35.
3. 3. Kucera H. Value and indication of radiotherapy in the endometrial carcinoma. Strahlenth. Onkol. 1991; 167; 381-386.
4. 4. Mittal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high risk and low risk groups. Cancer 1988; 61; 538-545.
5. 5. Homesley HD, Zaino R. Endometrial cancer. Prognostic factors. Sem. Oncol. 1994; 21; 71-78.
6. 6. Piver MS, Hempling RE. A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer 1990; 66; 1133-1138.
7. 7. Hancock KC, Freedman RS, Edwards CI. Use of cysplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat. Rep. 1986; 70; 789-791.
8. 8. Lentz SS. Advanced and recurrent endometrial carcinoma: hormonal therapy. Sem. Oncol. 1994; 21; 100-106.
9. 9. Hall PA, Richards MA, Gregor WM, d'Ardenne AJ. Sister TA, Stansfeld AG. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J. Pathol 1988; 154; 223-235.
10. 10. Kreipe H, Alm P, Olsson H, Hauberg M, Fischer L, Parwaresch R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am. J. Pathol. 1993; 142; 651-657.
11. 11. Quinn CM, Wright NA. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables. J. Pathol. 1990; 160; 93-102.
12. 12. Scott RJ, Hall PA, Haldane JS et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J. Pathol. 1991; 165; 173-178.
13. 13. Kreipe H, Wacker HH, Heidebrecht HJ et al. Determination of the growth fraction in Non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am. J. Pathol. 1993; 142; 1689-1694.
14. 14. Kellner U, Heidebrecht HJ, Rudolph P et al. Detection of human topoisomerase IIα in cell lines and tissues: characterization of five novel monoclonal antibodies. J. Histochem. Cytochem. 1997; 45; 251-263.
15. 15. Mikuta JJ. International Federation of Gynecology and Obstetrics Staging of endometrial cancer 1988. Cancer Suppl. 1993; 71; 1460-1463.
16. 16. Kurman JK. Grading of the endometrial carcinoma. Verh. Dtsch Ges. Pathol. 1991; 75; 376-377.
17. 17. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (eds). Tumors of the uterine corpus. World Health Organization. International histological classification of tumors. Histological typing of female genital tract tumors. Berlin, Heidelberg, New York: Springer Verlag, 1994.
18. 18. Kreipe H, Parwaresch R. A closer look at the cell cycle. Virch. Arch. A Pathol. Anat. 1993; 422; 341-343.
19. 19. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984; 133; 1710-1713.
20. 20. Kreipe H, Heidebrecht HJ, Hansen S et al. A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am. J. Pathol. 1993; 142; 3-9.
21. 21. DiSalvo CV, Zhang D, Jacobberger JW. Regulation of NIH-3T3 cell G1 phase transit by serum during exponential growth. Cell Prolif. 1995; 28; 511-524.
22. 22. Gerdes J, Li L, Schlueter C et al. Immunobiochemical and molecular biologic characterization of cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol. 1991; 138; 867-873.
23. 23. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J. Cell Physiol. 1987; 133; 579-584.
24. 24. Charpin C, Andrac L, Habib MC et al. Immunocytochemical assays in human endometrial carcinomas: a multiparametric computerized analysis and comparison with nonmalignant changes. Gynecol. Oncol. 1989; 33; 9-22.
25. 25. Pickartz H, Beckmann R, Fleige B, Düe W, Gerdes J, Stein H. Steroid receptors and proliferative activity in non-neoplastic and neoplastic endometria. Virch. Arch. A Pathol. Anat. 1990; 417; 163-171.
26. 26. Kogeguchi S, Hayase R, Sekiba K. Proliferative activity in normal endometrium and endometrial carcinoma measured by immunohistochemistry using the Ki-67 and anti-DNA polymerase α antibody, and by flow cytometry. Acta Med. Okayama 1992; 46; 113-121.
27. 27. Nordstrom B, Strang P, Bergstrom R. Nilsson S. Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67. proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 1996; 78; 1942-51.
28. 28. Susuni T, Rapi S, Savino L, Boddi V, Berti P, Massi G. Prognostic value of How cytometric deoxyribonucleic acid index In endometrial carcinoma: comparison with other clinical-pathologica parameters. Am.J. Obstet. Gynecol. 1994; 170; 527-534.
29. 29. Backe J. Gassel AM, Müller T, Schön S, Kaesemann H. Die Proliferationsrate als Prognosekriterium beim Endometriumkarzinom-eine immunhistochemische Analyse mit dem monoklonalen Antikörper Ki-S1. Zentrtalbl. Gyn Äkol. 1997; 119; 334-342.
30. 30. Kaleli S, Kosebay D, Bese T et al. A strong prognostic variable in endometrial carcinoma: flow cytometric S-phase fraction. Cancer 1997; 79; 944-951.